CJC-1295 (Drug Affinity Complex)

CJC-1295 w/ DAC – Long-Acting GHRH Analog for Growth Hormone and IGF-1 Research

Overview:
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone–releasing hormone (GHRH) studied for its ability to increase plasma growth hormone and IGF-1 levels through prolonged pituitary stimulation. The DAC modification significantly extends its biological half-life, allowing for sustained GH pulsatility and improved metabolic modeling in long-term research applications.

Scientific Background:
CJC-1295 functions by binding to GHRH receptors on somatotroph cells in the anterior pituitary, promoting cyclic GH release without suppressing natural feedback mechanisms. The addition of the DAC moiety (maleimidopropionyl linker) enables covalent binding to plasma proteins, extending its activity window to approximately 5–8 days in vivo models.
Research indicates potential benefits in lipid metabolism, muscle protein synthesis, tissue regeneration, and sleep regulation through indirect IGF-1 upregulation.

Why Researchers Study CJC-1295 w/ DAC:
CJC-1295 w/ DAC is a cornerstone in endocrine and longevity research, offering a reliable model for sustained GH and IGF-1 elevation. Its pharmacokinetic stability allows for efficient investigation of metabolic optimization, muscle regeneration, and anti-aging biology in controlled studies.

For Laboratory Research Use Only. Not for Human Consumption.